Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies

Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke MH, Ryan DP, Michelini A, Langford L, Meyerhardt J. Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol. 2005; A28.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.